Generate:Biomedicines, the Flagship-backed platform that uses AI to design protein therapeutics, filed for an IPO as it advances phase 3 and earlier-stage antibody and CAR-T programs. The filing highlights GB-0895 in Phase 3 for severe asthma and other AI-engineered candidates being pushed into clinical development. Generate’s move to the public markets reflects growing investor interest in machine-learning-enabled discovery and the willingness of Big Pharma to partner on AI-derived assets. The IPO will be tracked as a barometer for investor appetite toward AI-first drug companies.